Zileuton and Exhaled Nitric Oxide in Asthmatics

Completed · Phase 4

Conditions studied: Asthma

In brief

Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.

Key facts

Study ID

NCT00575861

Run by

Gelb, Arthur F., M.D.

People needed

19

Starts

2005-09-01

Expected to finish

2007-11-01

Last updated by the study team

2007-12-20

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non-smoking
• Moderate to severe persistent asthmatics
• Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months

You may not qualify if…

• No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks

Where it is running

• Arthur F Gelb Medical Corporation — Lakewood, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.